Failure Mode & Effects Analysis for Pharmaceutical Equipment

equipment modifications require change control and validation impact assessments; maintenance activities generate deviation investigations when they affect batch quality. In this environment, equipment failures cause batch deviations, product holds, FDA 483 observations, and consent decree risk. Our systematic FMEA and criticality analysis program specifically targets HVAC air handling units, lyophilizers, tablet presses, centrifuges, clean utility systems (WFI, clean steam), and packaging lines — the assets where early detection has the greatest impact on batch success rate and deviation closure time. We also account for strict change control requirements, adapting our measurement approach to maintain data quality despite these operating conditions.

Yes. Pharmaceutical facilities must comply with FDA 21 CFR Parts 210/211 cGMP, EU Annex 15 qualification, and ISPE GAMP 5 for computerized systems. Our systematic FMEA and criticality analysis program generates the condition documentation needed for cgmp-compliant maintenance documentation with audit trail, equipment qualification records, and calibration traceability. Beyond compliance, the condition data drives measurable improvements in batch success rate and deviation closure time by converting unplanned failures into scheduled repairs. Most pharmaceutical clients see meaningful reductions in batch deviations within the first 12 months of program implementation.

Direct experience at Pharmaceutical sites is non-negotiable. Generic industrial FMEA skills don't transfer cleanly to Pharmaceutical because of GMP validation, cleanroom equipment, batch traceability and the regulatory layer (FDA cGMP, EU Annex 15, ICH Q7). Ask for the lead analyst's hours of Pharmaceutical-specific work, certifications relevant to SAE J1739 and AIAG-VDA FMEA Handbook, and references from comparable plants in the same industry segment. Vendor-provided references screen positive almost universally — call them directly.

Baseline is analysis on new assets and after major modifications. Pharmaceutical environments often justify tighter intervals on a subset of assets — specifically those most exposed to sanitary pump reliability, clean utility integrity, batch traceability. The FMEA program scope at most Pharmaceutical sites we work with covers 30 to 80 critical assets in detail, with broader screening on the supporting equipment. Cost works out to $2K-$8K per major asset analysis for the detailed assets.